z-logo
open-access-imgOpen Access
Adverse Events Following COVID-19 Vaccination among the Beneficiaries of Sikkim Manipal University: A Cross Sectional Study
Author(s) -
Jayden Lhamu Bhutia,
Binu Upreti,
Eden Jamyang Bhutia,
Sumit Kar,
Forhad Akhtar Zaman
Publication year - 2021
Publication title -
indian journal of community health/indian journal of community health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.149
H-Index - 9
eISSN - 2248-9509
pISSN - 0971-7587
DOI - 10.47203/ijch.2021.v33i04.011
Subject(s) - medicine , adverse effect , vaccination , covid-19 , cross sectional study , pandemic , family medicine , environmental health , immunology , disease , pathology , infectious disease (medical specialty)
Background: Covid-19, an infection caused by SARS- CoV2 has claimed millions of lives since late 2019 with no curative measures. In India, 4 vaccines have been approved for use i.e. Serum Institute’s Covishield, Bharat Biotech’s Covaxin, GRIEM’s Sputnik V and Moderna’s Covid-19 vaccine. Aims: This study aims to find the adverse events following Covishield vaccination among the beneficiaries of Sikkim Manipal University, Sikkim. Material &Methods: A cross sectional study was conducted among the beneficiaries of Sikkim Manipal University to find out the adverse events following the first dose of vaccination. The data was collected using a self-administered questionnaire when the beneficiaries came for their second dose of vaccination. Microsoft Excel and SPSS version 27 was used for statistical analysis. Results: Out of 716 study participants majority i.e. 79.5% of the study participants developed adverse events following their first dose with maximum (73.8%) complaining of pain at the site of infection followed by fever (65.2%). Conclusions: Vaccines may prevent diseases, but it also brings about adverse effects, be it minor or major. Hence, many studies are required to study their full-fledged side effects and the means to overcome them.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here